Canaccord Genuity Initiates Coverage On Tango Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Neutral 59.0%

Neg 0% Neu 59% Pos 0%

Canaccord Genuity analyst John Newman initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces Price Target of $30.